2023 World Conference on Lung Cancer (Posters)-P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC

P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC - PDF(Slides)

Back to course

Pdf Summary

A retrospective study evaluated the efficacy of anti-PD-L1 therapy in patients with extensive-stage small cell lung cancer (ES-SCLC) and brain metastases. The study found that while anti-PD-L1 therapy improved overall survival (OS) in all patients, it did not reduce the risk of developing intracranial metastases in patients without baseline brain metastases.<br /><br />The study included 250 patients, of whom 124 received PD-L1 inhibitors as first-line therapy and 85 had baseline brain metastases. The addition of PD-L1 inhibitors prolonged the median OS for all patients compared to chemotherapy alone. In patients with baseline brain metastases, anti-PD-L1 therapy continued to provide a significant survival benefit. However, in patients without baseline brain metastases, immunotherapy did not delay the median time to develop brain progression or reduce the risk of developing intracranial metastases.<br /><br />The study highlights the survival benefit of immunotherapy in patients with ES-SCLC, especially those with brain metastases. However, it also indicates that immunotherapy may not effectively address the development of brain metastases in patients without baseline brain metastases.<br /><br />The present study retrospectively screened ES-SCLC patients and analyzed their outcomes based on the presence of baseline brain metastases and first-line treatment modalities. Overall survival, progression-free survival, intracranial progression-free survival, and cumulative incidence of brain metastases were calculated and compared using statistical methods.<br /><br />Further research and clinical implications are needed to determine the optimal management strategies for brain metastases from ES-SCLC. The contact information of the study author is provided for additional inquiries.

Asset Subtitle

Hui Zhu

Meta Tag

Speaker Hui Zhu

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

retrospective study

anti-PD-L1 therapy

extensive-stage small cell lung cancer

ES-SCLC

brain metastases

overall survival

intracranial metastases

PD-L1 inhibitors

chemotherapy

immunotherapy